Steven Cohen Mirati Therapeutics, Inc. Call Options Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $7.83 Million - $17.7 Million	200,000 New	200,000 $13.4 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $29.7 Million - $54.1 Million	-419,900 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$77.91 - $109.6 $32.7 Million - $46 Million	419,900 New	419,900 $32.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.